Introduction of a new staging system of breast cancer for radiologists: An emphasis on the prognostic stage

Jieun Koh, Min Jung Kim

Research output: Contribution to journalEditorial

2 Citations (Scopus)

Abstract

In 2017, the American Joint Committee on Cancer announced the 8th edition of its cancer staging system. For breast cancer, the most significant change in the staging system is the incorporation of biomarkers into the anatomic staging to create prognostic stages. Different prognostic stages are assigned to tumors with the same anatomic stages according to the tumor grade, hormone receptor (estrogen receptor; progesterone receptor) status, and HER2 status. A Clinical Prognostic Stage is assigned to all patients regardless of the type of therapy used; in contrast, a Pathologic Prognosis Stage is assigned to patients in whom surgery is the initial treatment. In a few situations, low Oncotype DX recurrence scores can change the prognostic stage. The radiologists need to understand the importance of the biologic factors that can influence cancer staging.

Original languageEnglish
Pages (from-to)69-82
Number of pages14
JournalKorean journal of radiology
Volume20
Issue number1
DOIs
Publication statusPublished - 2019 Jan

Fingerprint

Neoplasm Staging
Breast Neoplasms
Neoplasms
Biological Factors
Progesterone Receptors
Estrogen Receptors
Biomarkers
Hormones
Recurrence
Therapeutics
Radiologists

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

@article{6dd30e5fb4d44f8dbc23c49c20adb4e8,
title = "Introduction of a new staging system of breast cancer for radiologists: An emphasis on the prognostic stage",
abstract = "In 2017, the American Joint Committee on Cancer announced the 8th edition of its cancer staging system. For breast cancer, the most significant change in the staging system is the incorporation of biomarkers into the anatomic staging to create prognostic stages. Different prognostic stages are assigned to tumors with the same anatomic stages according to the tumor grade, hormone receptor (estrogen receptor; progesterone receptor) status, and HER2 status. A Clinical Prognostic Stage is assigned to all patients regardless of the type of therapy used; in contrast, a Pathologic Prognosis Stage is assigned to patients in whom surgery is the initial treatment. In a few situations, low Oncotype DX recurrence scores can change the prognostic stage. The radiologists need to understand the importance of the biologic factors that can influence cancer staging.",
author = "Jieun Koh and Kim, {Min Jung}",
year = "2019",
month = "1",
doi = "10.3348/kjr.2018.0231",
language = "English",
volume = "20",
pages = "69--82",
journal = "Korean Journal of Radiology",
issn = "1229-6929",
publisher = "Korean Radiological Society",
number = "1",

}

Introduction of a new staging system of breast cancer for radiologists : An emphasis on the prognostic stage. / Koh, Jieun; Kim, Min Jung.

In: Korean journal of radiology, Vol. 20, No. 1, 01.2019, p. 69-82.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - Introduction of a new staging system of breast cancer for radiologists

T2 - An emphasis on the prognostic stage

AU - Koh, Jieun

AU - Kim, Min Jung

PY - 2019/1

Y1 - 2019/1

N2 - In 2017, the American Joint Committee on Cancer announced the 8th edition of its cancer staging system. For breast cancer, the most significant change in the staging system is the incorporation of biomarkers into the anatomic staging to create prognostic stages. Different prognostic stages are assigned to tumors with the same anatomic stages according to the tumor grade, hormone receptor (estrogen receptor; progesterone receptor) status, and HER2 status. A Clinical Prognostic Stage is assigned to all patients regardless of the type of therapy used; in contrast, a Pathologic Prognosis Stage is assigned to patients in whom surgery is the initial treatment. In a few situations, low Oncotype DX recurrence scores can change the prognostic stage. The radiologists need to understand the importance of the biologic factors that can influence cancer staging.

AB - In 2017, the American Joint Committee on Cancer announced the 8th edition of its cancer staging system. For breast cancer, the most significant change in the staging system is the incorporation of biomarkers into the anatomic staging to create prognostic stages. Different prognostic stages are assigned to tumors with the same anatomic stages according to the tumor grade, hormone receptor (estrogen receptor; progesterone receptor) status, and HER2 status. A Clinical Prognostic Stage is assigned to all patients regardless of the type of therapy used; in contrast, a Pathologic Prognosis Stage is assigned to patients in whom surgery is the initial treatment. In a few situations, low Oncotype DX recurrence scores can change the prognostic stage. The radiologists need to understand the importance of the biologic factors that can influence cancer staging.

UR - http://www.scopus.com/inward/record.url?scp=85059645475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059645475&partnerID=8YFLogxK

U2 - 10.3348/kjr.2018.0231

DO - 10.3348/kjr.2018.0231

M3 - Editorial

C2 - 30627023

AN - SCOPUS:85059645475

VL - 20

SP - 69

EP - 82

JO - Korean Journal of Radiology

JF - Korean Journal of Radiology

SN - 1229-6929

IS - 1

ER -